Experimental mobile app helps manage migraines
(Reuters Health) – A smartphone-based relaxation app could help migraine sufferers reduce the number of headaches they get each month,…
FDA approves Lilly’s migraine drug as first ever cluster headache treatment
NEW YORK (Reuters) – Eli Lilly and Co’s migraine treatment Emgality on Tuesday became the first drug to gain U.S.…
U.S. regulator approves Teva migraine drug, shares rise
(Reuters) – Shares of Israeli drugmaker Teva Pharmaceutical Industries rose over 5 percent in after-hours trading on Friday after the…
U.S. medical device firm electroCore IPO price set at $15 per share
(Reuters) – U.S. medical device maker electroCore Llc’s initial public offering is expected to price at $15 per share, Chief…
Novartis readies anti-sexism message for migraine drug
ZURICH (Reuters) – With women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to…
Allergan migraine drug succeeds in second late-stage trial
NEW YORK (Reuters) – Allergan Plc on Friday announced positive results from a second Phase III trial for the 50…
Biohaven plunges as investors pit migraine data against Allergan’s drug
(Reuters) – Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its…